On-farm pregnancy rates in both breeds were higher than previously reported and likely reflect improvements in reproductive management. The disparity between breeds in the inseminations per cycle and proportion of barren mares exposed the differing structures of the two industries, and presents a target for improving the reproductive efficiency in STBs. The difference between breeds in the multiple pregnancy rate per cycle likely reflects the higher ovulation rate of TB mares. The variability in pregnancy rate per cycle between the 22 stallions was associated with differences in individual inherent fertility and the quality of stallion management.
Background: Atrial fibrillation (AF) impacts performance and horse and jockey safety. Understanding the outcomes of AF identified postrace will better inform regulatory policy. Hypothesis/Objectives: To investigate the outcomes after episodes of AF identified postrace and determine whether affected horses are at increased risk of additional episodes compared to the general racing population. Animals: Total of 4684 Thoroughbred racehorses. Methods: Race records for Thoroughbred horses racing in Hong Kong from 2007 to 2017 were reviewed. Horses that performed below expectation were examined by cardiac auscultation and ECG. Incidence and recurrence of AF were compared between horses with and without a history of AF and between horses with paroxysmal and persistent episodes using Fisher's exact test. Results: There were 96 135 race starts during the study. Atrial fibrillation was identified in 4.9% of horses, with an overall incidence of 2.7 episodes per 1000 starts. The incidence of AF in horses after any previous episode (12.8 per 1000 starts) was higher than for horses with no previous episode (2.4 per 1000 starts; odds ratio [OR], 5.3; 95% confidence interval [CI], 3.8-7.6). Recurrence was seen in 64% of horses previously treated for persistent AF, which was higher than recurrence in horses with paroxysmal AF (23%; OR, 5.9; 95% CI, 1.6-21.2). Median duration between episodes was 343 days (range, 34-1065). Conclusions and Clinical Importance: Thoroughbreds are at increased risk of recurrent AF after both paroxysmal and persistent episodes, but the duration of time between episodes varies widely. These findings support a substantial burden of AF among individual Thoroughbred racehorses.
cTnI is elevated in horses with myocardial disease and elevated to a lesser degree in some horses with structural heart disease or lone arrhythmias. The association between cTnI concentration and survival was not clear.
SummaryA Thoroughbred gelding had chronic episodic intra-abdominal haemorrhage following standing castration, presumed to originate from a testicular artery. No coagulopathy could be detected and resolution of haemorrhage was achieved by laparoscopic electrocoagulation of both testicular arteries 6 weeks after castration. Blood drained from the abdomen during surgery was filtered then auto-transfused. Post operative complications included pigmenturia, incisional pain and large colon impaction.
A 10-week-old Thoroughbred filly was referred for anaemia of 4 weeks' duration. Haematology revealed severe anaemia and panleucopenia. Cytological examination of bone marrow smears revealed a myeloid to erythroid ratio <0.02:1 (reference range 0.5-2.4:1.0) and an abundance of erythroid precursor cells. The erythroid cell population included rubriblasts, prorubricytes and rubricytes, with only scant numbers of metarubricytes present. There were numerous mitotic erythroid cells, some of which were atypical and megaloblastic. These cytomorphological changes are consistent with pure acute erythroid leukaemia. No treatment was instituted and the filly died three days after presentation. This case illustrates the need to consider both haematology and bone marrow findings to establish a diagnosis of pure erythroid leukaemia. To our knowledge, there is no documented case of acute myeloproliferative disease in horses involving cells of erythroid lineage, but this condition should be considered a differential diagnosis for horses presenting with anaemia.
Evidence of myocardial injury was observed in horses with acute abdominal disease, and this injury was associated with severity of illness. Recognition of myocardial injury could improve treatment of acute abdominal disease in horses.
BackgroundAcute gastrointestinal disease occurs commonly in horses. Novel biomarkers might improve the understanding of SIRS and aid diagnosis and determination of prognosis.HypothesesIncreased plasma concentrations of the biomarkers HMGB‐1 and nucleosomes are associated with severity of gastrointestinal lesions in horses; concentrations of these biomarkers will be greater in horses with lesions more likely to cause SIRS; and will provide additional information compared with standard biomarkers fibrinogen and SAA.AnimalsThirty horses with gastrointestinal disease, 22 healthy horses.MethodsProspective study. Plasma samples taken on admission were used for measurement of HMGB‐1, nucleosomes, fibrinogen, and SAA. Values were compared between healthy horses and those with gastrointestinal disease, and between horses with gastrointestinal disease grouped by lesion type (inflammatory, strangulating, and nonstrangulating). Correlations between biomarkers were assessed.ResultsPlasma concentrations of all biomarkers were significantly higher in horses with gastrointestinal disease compared to healthy horses (P ≤ .001). HMGB‐1 and nucleosomes were significantly higher in inflammatory and strangulating groups compared to healthy horses (3.5‐fold and 5.4‐fold increases, respectively, for HMGB‐1 (P < .05) and 4.8‐fold and 5.6‐fold increases for nucleosomes (P < .05)), but concentrations in the group with nonstrangulating disease did not differ from healthy horses. There was significant correlation between HMGB‐1 and nucleosomes (Spearman's r = 0.623; P < .001), and fibrinogen and SAA (Spearman's r = 0.801; P < .001) but not between other biomarkers.Conclusions and Clinical ImportanceHigh mobility group box‐1 and nucleosomes might have use as biomarkers for horses with gastrointestinal disease. Further studies are required to determine kinetics and prognostic value of serial measurements of these biomarkers in horses.
OBJECTIVE-To assess the use of stored equine colostrum for the treatment of foals perceived to be at risk for failure of transfer of passive immunity (FTPI). DESIGN-Cohort study. ANIMALS-232 Thoroughbred foals and 191 Thoroughbred mares (41 mares gave birth to 1 foal on 2 occasions). PROCEDURES-Postpartum, presuckle colostrum samples were collected from mares; samples with a colostral refractive index (cRI) > or = 23% were frozen (-20 degrees C [-4 degrees F]) and stored for > or = 7 days but < 2 years. Foals of dams that produced colostrum with a cRI value < 20% were treated with > or = 300 mL of stored colostrum that was thawed and administered via nasogastric tube on 1 to 4 occasions within 6 hours after parturition. Serum samples were obtained from colostrum-treated and nontreated foals 24 hours after treatment or suckling, respectively, for determination of serum IgG (sIgG) concentration. RESULTS-8 foals and their respective dams were excluded from the analyses. For the remaining 30 treated and 194 nontreated foals, mean +/- SD sIgG concentration was 1,597 +/- 574 mg/dL. Thirteen (5.8%) foals had sIgG concentrations < 800 mg/dL, of which 1 (0.4%) had an sIgG concentration < 400 mg/dL. Nine of these foals had suckled mares producing colostrum with a cRI value > or = 20%, and 2 foals had been treated with stored colostrum. CONCLUSIONS AND CLINICAL RELEVANCE-Treatment with stored colostrum appeared to be effective for prevention of FTPI in at-risk foals. However, foals were still at risk for FTPI despite suckling of or treatment with colostrum with adequate cRI values.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.